Interventional Cardiology Devices Market Insights, Competitive Landscape and Market Forecast–2026
This report can be delivered to the clients within 7-10 Business Days
INTERVENTIONAL CARDIOLOGY DEVICES MARKET BY PRODUCT (ANGIOPLASTY BALLOONS [DRUG-ELUTING BALLOONS AND OTHERS], ANGIOPLASTY STENTS [DRUG-ELUTING STENTS, BARE-METAL STENTS, AND BIOABSORBABLE STENTS], STRUCTURAL HEART DEVICES [AORTIC VALVE THERAPY DEVICES AND OTHERS], CATHETERS [ANGIOGRAPHY CATHETERS, GUIDING CATHETERS AND IVUS/OCT CATHETERS], PLAQUE MODIFICATION DEVICES [ATHERECTOMY DEVICES AND THROMBECTOMY DEVICES], HEMODYNAMIC FLOW ALTERATION DEVICES [EMBOLIC PROTECTION DEVICES AND CHRONIC TOTAL OCCLUSION DEVICES], OTHER DEVICES), BY GEOGRAPHY, IS EXPECTED TO GROW AT A STEADY CAGR FORECAST TILL 2026 OWING TO RISING TECHNOLOGICAL ADVANCEMENT AND INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES
Global Interventional Cardiology Devices Market was valued at USD 12.41 billion in 2020, growing at a CAGR of 6.53% during the forecast period from 2021 to 2026, to reach USD 18.36 billion by 2026. The demand for Interventional Cardiology Devices is primarily being boosted by the growing prevalence of cardiovascular diseases (CVDs) in the rising geriatric population, technological advancements in product development, the increasing adoption rates of minimally invasive surgeries, and increasing awareness programs regarding cardiovascular diseases. However, the availability of alternative treatments and product recalls are the major factors that are expected to restrain the growth of the Interventional Cardiology Devices market during the forecast period.
INTERVENTIONAL CARDIOLOGY DEVICES MARKET DYNAMICS:
Interventional Cardiology devices are used in the diagnosis and treatment of patients suffering from cardiovascular diseases. Such procedures lead to fewer patient injuries and ensure a faster recovery and, therefore, shorter hospital time. High demand for novel products with high precision and efficiency is thus expected to boost the market growth. Moreover, due to unhealthy lifestyle habits, such as consumption of excess salt, saturated fats, and sugars, lack of physical activity, high tobacco and alcohol consumption, the dominance of diseases has increased, which further escalates the growth of the Interventional Cardiology Devices market.
As per the data provided by the World Health Organization, cardiovascular diseases are the leading cause of death across the globe, wherein this group of diseases accounts for an estimated 17.9 million lives each year. Furthermore, the same data by the WHO presented that over four out of five CVD deaths list strokes and heart attacks as the main cause, and one-third of these deaths are said to occur prematurely in people below 70 years of age. Over three-quarters of CVD deaths take place in low- and middle-income countries.
According to the data provided by the European Society for Cardiology (ESC), each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. They represent about 45% of all deaths in Europe and 37% in the EU.
Additionally, as per the data provided by the WHO for Europe, deaths, where CVD is listed as a cause, are about 46 times higher in Europe.
According to the British Heart Foundation, as of June 2020, there were 2.3 million people in the UK living with CAD. Each year, 170,000 people die from heart and circulatory diseases in the UK.
The above-mentioned facts state the dire need for measures to address the rising disease burden of CVDs across the globe. Indications such as atherosclerosis, arrhythmias can affect the quality of life of patients. Therefore, the Global Interventional Cardiology Devices market is expected to witness remarkable growth during the forecast period due to the rising global prevalence of CVDs.
However, the non-availability of the advanced products, product recalls, high treatment costs and limitations regarding the safety of devices may prove to be certain restraints to the Interventional Cardiology Devices market growth.
INTERVENTIONAL CARDIOLOGY DEVICES MARKET SEGMENT ANALYSIS:
Interventional Cardiology Devices by Product (Angioplasty Balloons [Drug-Eluting Balloons and Others], Angioplasty Stents [Drug-Eluting Stents, Bare-Metal Stents, and Bioabsorbable Stents], Structural Heart Devices [Aortic Valve Therapy Devices and Others], Catheters [Angiography Catheters, Guiding Catheters and IVUS/OCT Catheters], Plaque Modification Devices [Atherectomy Devices and Thrombectomy Devices], Hemodynamic Flow Alteration Devices [Embolic Protection Devices and Chronic Total Occlusion Devices], Other Devices), and Interventional Cardiology Devices market by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
Interventional Cardiology Devices market product segment, the Angiography Catheters market segment will hold the majority of the Global Interventional Cardiology Devices market. This is due to the high and increasing prevalence of coronary artery diseases (CAD), coupled with the growing awareness about the benefits of the early diagnosis of CADs. Furthermore, technological advancements and product innovations taking place in the development of Angiography Catheters devices are likely to propel Global Interventional Cardiology Devices market growth.
In addition, the hemodynamic flow alteration devices market has been categorized into embolic protection devices and chronic total occlusion devices. Among both, the embolic protection devices segment accounts for the largest share of the hemodynamic flow alteration devices market. This can be attributed to the advantages of embolic protection devices over chronic total occlusion devices, such as the ability to capture embolic debris without interrupting continuous blood flow. Moreover, an increasing number of interventional procedures for treating coronary artery diseases will propel the growth of the Global Interventional Cardiology Devices market.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL INTERVENTIONAL CARDIOLOGY DEVICES MARKET:
North America is expected to dominate the overall Interventional Cardiology Devices market during the forecast period. The growing prevalence of cardiovascular diseases, access to better healthcare infrastructure coupled with the presence of major market players in the region are predicted to be the major influencing factors in driving the overall growth of the Global Interventional Cardiology Devices market.
As per the Centers for Disease Prevention and Control (CDC), heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States where about 655,000 Americans die from heart disease each year.
In addition to the above numbers, the data provided by the American Heart Association mentioned that chronic heart disease remains the leading cause of death in the US, according to the 2018 data. The data sheet indicated that in 2018, CHD accounted for approximately 13% of deaths in the US causing 365,744 deaths.
The well-established healthcare infrastructure in the country with supportive reimbursement programs covering the costs for the implantable devices as well as the procedure further encourage people to opt for such devices.
Considering the presence of a large patient pool in the US coupled with new product launches, the market for Interventional Cardiology Devices looks promising in the United States.
INTERVENTIONAL CARDIOLOGY DEVICES MARKET KEY PLAYERS:
Some of the key market players operating in the Interventional Cardiology Devices market include Edwards Lifesciences Corporation, Abbott Laboratories, Boston Scientific Corporation, ACIST Medical Systems, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, Medtronic PLC., Teleflex Incorporated, B Braun Melsungen AG, MicroPort Scientific Corporation, SIS MEDICAL AG Lepu Medical Technology Co. Ltd., Terumo Corporation, Sahajanand Laser Technology Limited, Biotronik SE & Co. KG and others.
RECENT DEVELOPMENTAL ACTIVITIES IN THE INTERVENTIONAL CARDIOLOGY DEVICES MARKET:
? In July 2021, Medtronic PLC, the global leader in medical technology, announced the launch of the Prevail™ drug-coated balloon (DCB) Catheter in Europe following the CE (Conformitй Europйene) mark. The newest coronary DCB on the market, the Prevail DCB is used during percutaneous coronary intervention (PCI) procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease (CAD).
? In June 2020, Edward Lifesciences Corporation (US) has received Chinese regulatory approval for the SAPIEN 3 Transcatheter Heart Valve for the treatment of patients suffering from severe, symptomatic aortic stenosis (AS) who are unable to undergo open-heart surgery.
KEY TAKES AWAY FROM THE INTERVENTIONAL CARDIOLOGY DEVICES MARKET REPORT STUDY
? Market size analysis for current market size (2020), and market forecast for 5 years (2021-2026)
? The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Interventional Cardiology Devices market.
? Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
? Key companies dominating the Global Interventional Cardiology Devices Market.
? Various opportunities are available for the other competitor in the Interventional Cardiology Devices Market space.
? What are the top-performing segments in 2020? How these segments will perform in 2026.
? Which are the top-performing regions and countries in the current market scenario?
? Which are the regions and countries where companies should have concentrated on opportunities for Interventional Cardiology Devices market growth in the coming future?
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS INTERVENTIONAL CARDIOLOGY DEVICES MARKET KET REPORT STUDY
? Interventional Cardiology Devices providers
? Research organizations and consulting companies
? Interventional Cardiology Devices related organization, association, forum, and other alliances
? Government and corporate offices
? Start-up companies, venture capitalists, and private equity firms
? Distributors and Traders in Interventional Cardiology Devices
? Various End-users want to know more about the Interventional Cardiology Devices Market and the latest technological developments in the Interventional Cardiology Devices market.
FREQUENTLY ASKED QUESTIONS FOR INTERVENTIONAL CARDIOLOGY DEVICES MARKET:
What are Interventional Cardiology Devices?
Interventional Cardiology devices are used in the diagnosis and treatment of patients suffering from cardiovascular diseases. Such procedures lead to fewer patient injuries and ensure a faster recovery and, therefore, shorter hospital time.
What is the market for Global Interventional Cardiology Devices?
Global Interventional Cardiology Devices Market was valued at USD 12.41 billion in 2020, growing at a CAGR of 6.53% during the forecast period from 2021 to 2026, to reach USD 18.36 billion by 2026.
What are the drivers for Global Interventional Cardiology Devices?
The major drivers driving the demand for Interventional Cardiology Devices are the growing prevalence of cardiovascular diseases (CVDs) in the rising geriatric population, technological advancements in product development, the increasing adoption rates of minimally invasive surgeries, and increasing awareness programs regarding cardiovascular diseases.
What are the key players operating in Global Interventional Cardiology Devices?
Some of the key market players operating in the Interventional Cardiology Devices market include Edwards Lifesciences Corporation, Abbott Laboratories, Boston Scientific Corporation, ACIST Medical Systems, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, Medtronic PLC., Teleflex Incorporated, B Braun Melsungen AG, MicroPort Scientific Corporation, SIS MEDICAL AG Lepu Medical Technology Co. Ltd., Terumo Corporation, Sahajanand Laser Technology Limited, Biotronik SE & Co. KG and others.
What regions have the highest share in the Interventional Cardiology Devices market?
North America is expected to dominate the overall Interventional Cardiology Devices market during the forecast period, 2021 to 2026. This domination is due to the growing prevalence of cardiovascular diseases, access to better healthcare infrastructure coupled with the presence of major market players in the region.
INTERVENTIONAL CARDIOLOGY DEVICES MARKET BY PRODUCT (ANGIOPLASTY BALLOONS [DRUG-ELUTING BALLOONS AND OTHERS], ANGIOPLASTY STENTS [DRUG-ELUTING STENTS, BARE-METAL STENTS, AND BIOABSORBABLE STENTS], STRUCTURAL HEART DEVICES [AORTIC VALVE THERAPY DEVICES AND OTHERS], CATHETERS [ANGIOGRAPHY CATHETERS, GUIDING CATHETERS AND IVUS/OCT CATHETERS], PLAQUE MODIFICATION DEVICES [ATHERECTOMY DEVICES AND THROMBECTOMY DEVICES], HEMODYNAMIC FLOW ALTERATION DEVICES [EMBOLIC PROTECTION DEVICES AND CHRONIC TOTAL OCCLUSION DEVICES], OTHER DEVICES), BY GEOGRAPHY, IS EXPECTED TO GROW AT A STEADY CAGR FORECAST TILL 2026 OWING TO RISING TECHNOLOGICAL ADVANCEMENT AND INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES
Global Interventional Cardiology Devices Market was valued at USD 12.41 billion in 2020, growing at a CAGR of 6.53% during the forecast period from 2021 to 2026, to reach USD 18.36 billion by 2026. The demand for Interventional Cardiology Devices is primarily being boosted by the growing prevalence of cardiovascular diseases (CVDs) in the rising geriatric population, technological advancements in product development, the increasing adoption rates of minimally invasive surgeries, and increasing awareness programs regarding cardiovascular diseases. However, the availability of alternative treatments and product recalls are the major factors that are expected to restrain the growth of the Interventional Cardiology Devices market during the forecast period.
INTERVENTIONAL CARDIOLOGY DEVICES MARKET DYNAMICS:
Interventional Cardiology devices are used in the diagnosis and treatment of patients suffering from cardiovascular diseases. Such procedures lead to fewer patient injuries and ensure a faster recovery and, therefore, shorter hospital time. High demand for novel products with high precision and efficiency is thus expected to boost the market growth. Moreover, due to unhealthy lifestyle habits, such as consumption of excess salt, saturated fats, and sugars, lack of physical activity, high tobacco and alcohol consumption, the dominance of diseases has increased, which further escalates the growth of the Interventional Cardiology Devices market.
As per the data provided by the World Health Organization, cardiovascular diseases are the leading cause of death across the globe, wherein this group of diseases accounts for an estimated 17.9 million lives each year. Furthermore, the same data by the WHO presented that over four out of five CVD deaths list strokes and heart attacks as the main cause, and one-third of these deaths are said to occur prematurely in people below 70 years of age. Over three-quarters of CVD deaths take place in low- and middle-income countries.
According to the data provided by the European Society for Cardiology (ESC), each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. They represent about 45% of all deaths in Europe and 37% in the EU.
Additionally, as per the data provided by the WHO for Europe, deaths, where CVD is listed as a cause, are about 46 times higher in Europe.
According to the British Heart Foundation, as of June 2020, there were 2.3 million people in the UK living with CAD. Each year, 170,000 people die from heart and circulatory diseases in the UK.
The above-mentioned facts state the dire need for measures to address the rising disease burden of CVDs across the globe. Indications such as atherosclerosis, arrhythmias can affect the quality of life of patients. Therefore, the Global Interventional Cardiology Devices market is expected to witness remarkable growth during the forecast period due to the rising global prevalence of CVDs.
However, the non-availability of the advanced products, product recalls, high treatment costs and limitations regarding the safety of devices may prove to be certain restraints to the Interventional Cardiology Devices market growth.
INTERVENTIONAL CARDIOLOGY DEVICES MARKET SEGMENT ANALYSIS:
Interventional Cardiology Devices by Product (Angioplasty Balloons [Drug-Eluting Balloons and Others], Angioplasty Stents [Drug-Eluting Stents, Bare-Metal Stents, and Bioabsorbable Stents], Structural Heart Devices [Aortic Valve Therapy Devices and Others], Catheters [Angiography Catheters, Guiding Catheters and IVUS/OCT Catheters], Plaque Modification Devices [Atherectomy Devices and Thrombectomy Devices], Hemodynamic Flow Alteration Devices [Embolic Protection Devices and Chronic Total Occlusion Devices], Other Devices), and Interventional Cardiology Devices market by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
Interventional Cardiology Devices market product segment, the Angiography Catheters market segment will hold the majority of the Global Interventional Cardiology Devices market. This is due to the high and increasing prevalence of coronary artery diseases (CAD), coupled with the growing awareness about the benefits of the early diagnosis of CADs. Furthermore, technological advancements and product innovations taking place in the development of Angiography Catheters devices are likely to propel Global Interventional Cardiology Devices market growth.
In addition, the hemodynamic flow alteration devices market has been categorized into embolic protection devices and chronic total occlusion devices. Among both, the embolic protection devices segment accounts for the largest share of the hemodynamic flow alteration devices market. This can be attributed to the advantages of embolic protection devices over chronic total occlusion devices, such as the ability to capture embolic debris without interrupting continuous blood flow. Moreover, an increasing number of interventional procedures for treating coronary artery diseases will propel the growth of the Global Interventional Cardiology Devices market.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL INTERVENTIONAL CARDIOLOGY DEVICES MARKET:
North America is expected to dominate the overall Interventional Cardiology Devices market during the forecast period. The growing prevalence of cardiovascular diseases, access to better healthcare infrastructure coupled with the presence of major market players in the region are predicted to be the major influencing factors in driving the overall growth of the Global Interventional Cardiology Devices market.
As per the Centers for Disease Prevention and Control (CDC), heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States where about 655,000 Americans die from heart disease each year.
In addition to the above numbers, the data provided by the American Heart Association mentioned that chronic heart disease remains the leading cause of death in the US, according to the 2018 data. The data sheet indicated that in 2018, CHD accounted for approximately 13% of deaths in the US causing 365,744 deaths.
The well-established healthcare infrastructure in the country with supportive reimbursement programs covering the costs for the implantable devices as well as the procedure further encourage people to opt for such devices.
Considering the presence of a large patient pool in the US coupled with new product launches, the market for Interventional Cardiology Devices looks promising in the United States.
INTERVENTIONAL CARDIOLOGY DEVICES MARKET KEY PLAYERS:
Some of the key market players operating in the Interventional Cardiology Devices market include Edwards Lifesciences Corporation, Abbott Laboratories, Boston Scientific Corporation, ACIST Medical Systems, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, Medtronic PLC., Teleflex Incorporated, B Braun Melsungen AG, MicroPort Scientific Corporation, SIS MEDICAL AG Lepu Medical Technology Co. Ltd., Terumo Corporation, Sahajanand Laser Technology Limited, Biotronik SE & Co. KG and others.
RECENT DEVELOPMENTAL ACTIVITIES IN THE INTERVENTIONAL CARDIOLOGY DEVICES MARKET:
? In July 2021, Medtronic PLC, the global leader in medical technology, announced the launch of the Prevail™ drug-coated balloon (DCB) Catheter in Europe following the CE (Conformitй Europйene) mark. The newest coronary DCB on the market, the Prevail DCB is used during percutaneous coronary intervention (PCI) procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease (CAD).
? In June 2020, Edward Lifesciences Corporation (US) has received Chinese regulatory approval for the SAPIEN 3 Transcatheter Heart Valve for the treatment of patients suffering from severe, symptomatic aortic stenosis (AS) who are unable to undergo open-heart surgery.
KEY TAKES AWAY FROM THE INTERVENTIONAL CARDIOLOGY DEVICES MARKET REPORT STUDY
? Market size analysis for current market size (2020), and market forecast for 5 years (2021-2026)
? The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Interventional Cardiology Devices market.
? Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
? Key companies dominating the Global Interventional Cardiology Devices Market.
? Various opportunities are available for the other competitor in the Interventional Cardiology Devices Market space.
? What are the top-performing segments in 2020? How these segments will perform in 2026.
? Which are the top-performing regions and countries in the current market scenario?
? Which are the regions and countries where companies should have concentrated on opportunities for Interventional Cardiology Devices market growth in the coming future?
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS INTERVENTIONAL CARDIOLOGY DEVICES MARKET KET REPORT STUDY
? Interventional Cardiology Devices providers
? Research organizations and consulting companies
? Interventional Cardiology Devices related organization, association, forum, and other alliances
? Government and corporate offices
? Start-up companies, venture capitalists, and private equity firms
? Distributors and Traders in Interventional Cardiology Devices
? Various End-users want to know more about the Interventional Cardiology Devices Market and the latest technological developments in the Interventional Cardiology Devices market.
FREQUENTLY ASKED QUESTIONS FOR INTERVENTIONAL CARDIOLOGY DEVICES MARKET:
What are Interventional Cardiology Devices?
Interventional Cardiology devices are used in the diagnosis and treatment of patients suffering from cardiovascular diseases. Such procedures lead to fewer patient injuries and ensure a faster recovery and, therefore, shorter hospital time.
What is the market for Global Interventional Cardiology Devices?
Global Interventional Cardiology Devices Market was valued at USD 12.41 billion in 2020, growing at a CAGR of 6.53% during the forecast period from 2021 to 2026, to reach USD 18.36 billion by 2026.
What are the drivers for Global Interventional Cardiology Devices?
The major drivers driving the demand for Interventional Cardiology Devices are the growing prevalence of cardiovascular diseases (CVDs) in the rising geriatric population, technological advancements in product development, the increasing adoption rates of minimally invasive surgeries, and increasing awareness programs regarding cardiovascular diseases.
What are the key players operating in Global Interventional Cardiology Devices?
Some of the key market players operating in the Interventional Cardiology Devices market include Edwards Lifesciences Corporation, Abbott Laboratories, Boston Scientific Corporation, ACIST Medical Systems, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, Medtronic PLC., Teleflex Incorporated, B Braun Melsungen AG, MicroPort Scientific Corporation, SIS MEDICAL AG Lepu Medical Technology Co. Ltd., Terumo Corporation, Sahajanand Laser Technology Limited, Biotronik SE & Co. KG and others.
What regions have the highest share in the Interventional Cardiology Devices market?
North America is expected to dominate the overall Interventional Cardiology Devices market during the forecast period, 2021 to 2026. This domination is due to the growing prevalence of cardiovascular diseases, access to better healthcare infrastructure coupled with the presence of major market players in the region.
1. INTERVENTIONAL CARDIOLOGY DEVICES MARKET REPORT INTRODUCTION
2. INTERVENTIONAL CARDIOLOGY DEVICES MARKET EXECUTIVE SUMMARY
2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1 The United States
3.2 Europe
3.2.1 Germany
3.2.2 France
3.2.3 Italy
3.2.4 Spain
3.2.5 The U.K.
3.3 Japan
4. INTERVENTIONAL CARDIOLOGY DEVICES MARKET KEY FACTORS ANALYSIS
4.1 Interventional Cardiology Devices Market Drivers
4.1.1 Growing prevalence of cardiovascular diseases (CVDs) in the rising geriatric population
4.1.2 Technological advancements in product development
4.1.3 Increasing adoption rates of minimally invasive surgeries
4.1.4 Increasing awareness programs regarding cardiovascular diseases
4.2 Interventional Cardiology Devices Market Restraints and Challenges
4.2.1 Availability of alternative treatments
4.2.2 Product recalls
4.3 Interventional Cardiology Devices Market Opportunities
4.3.1 Increasing health awareness in emerging countries
4.3.2 Use and availability of stents – which is bio-adaptive, smart, and anti-bacterial
5. INTERVENTIONAL CARDIOLOGY DEVICES PORTER’S FIVE FORCES ANALYSIS
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry
6. COVID-19 IMPACT ANALYSIS ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET
7. INTERVENTIONAL CARDIOLOGY DEVICES MARKET LAYOUT
7.1 By Product
7.1.1 Angioplasty Balloons
7.1.1.1 Drug-Eluting Balloons
7.1.1.2 Others
7.1.2 Angioplasty Stents
7.1.2.1 Drug-Eluting Stents
7.1.2.2 Bare-Metal Stents
7.1.2.3 Bioabsorbable Stents
7.1.3 Structural Heart Devices
7.1.3.1 Aortic Valve Therapy Devices
7.1.3.2 Others
7.1.4 Catheters
7.1.4.1 Angiography Catheters
7.1.4.2 Guiding Catheters
7.1.4.3 IVUS/OCT Catheters
7.1.5 Plaque Modification Devices
7.1.5.1 Atherectomy Devices
7.1.5.2 Thrombectomy Devices
7.1.6 Hemodynamic Flow Alteration Devices
7.1.6.1 Embolic Protection Devices
7.1.6.2 Chronic Total Occlusion Devices
7.1.7 Other Devices
7.2 By Geography
7.2.1 North America
7.2.1.1 North America Interventional Cardiology Devices Market, by Product
7.2.1.2 North America Interventional Cardiology Devices Market, by Country
7.2.1.2.1 United States
7.2.1.2.2 Canada
7.2.1.2.3 Mexico
7.2.2 Europe
7.2.2.1 Europe Interventional Cardiology Devices Market, by Product
7.2.2.2 Europe Interventional Cardiology Devices Market, by Country
7.2.2.2.1 France
7.2.2.2.2 Germany
7.2.2.2.3 United Kingdom
7.2.2.2.4 Italy
7.2.2.2.5 Spain
7.2.2.2.6 Russia
7.2.2.2.7 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 Asia-Pacific Interventional Cardiology Devices Market, by Product
7.2.3.2 Asia-Pacific Interventional Cardiology Devices Market, by Country
7.2.3.2.1 China
7.2.3.2.2 Japan
7.2.3.2.3 India
7.2.3.2.4 Australia
7.2.3.2.5 South Korea
7.2.3.2.6 Rest of Asia Pacific
7.2.4 Rest of the World (RoW)
7.2.4.1 RoW Interventional Cardiology Devices Market, by Product
7.2.4.2 RoW Interventional Cardiology Devices Market, by Region
7.2.4.2.1 Middle East
7.2.4.2.2 Africa
7.2.4.2.3 South America
8. INTERVENTIONAL CARDIOLOGY DEVICES GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. INTERVENTIONAL CARDIOLOGY DEVICES COMPANY AND PRODUCT PROFILES
9.1 Edwards Lifesciences Corporation
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4 Product Listing
9.1.5. Entropy
9.2 Abbott Laboratories
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4 Product Listing
9.2.5. Entropy
9.3 Boston Scientific Corporation
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4 Product Listing
9.3.5. Entropy
9.4 ACIST Medical Systems
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4 Product Listing
9.4.5. Entropy
9.5 F. Hoffmann-La Roche Ltd
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4 Product Listing
9.5.5. Entropy
9.6 Siemens Healthcare GmbH
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4 Product Listing
9.6.5. Entropy
9.7 Medtronic PLC.
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4 Product Listing
9.7.5. Entropy
9.8 Teleflex Incorporated
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4 Product Listing
9.8.5. Entropy
9.9 B Braun Melsungen AG
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4 Product Listing
9.9.5. Entropy
9.10 MicroPort Scientific Corporation
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4 Product Listing
9.10.5. Entropy
9.11 SIS MEDICAL AG
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4 Product Listing
9.11.5. Entropy
9.12 Lepu Medical Technology Co. Ltd.
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4 Product Listing
9.12.5. Entropy
9.13 Terumo Corporation
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4 Product Listing
9.13.5. Entropy
9.14 Sahajanand Laser Technology Limited
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4 Product Listing
9.14.5. Entropy
9.15 Biotronik SE & Co. KG
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4 Product Listing
9.15.5. Entropy
10. PROJECT APPROACH
10.1 Secondary Sources
10.2 Primary Sources
10.3 Data Triangulation
10.4 Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
2. INTERVENTIONAL CARDIOLOGY DEVICES MARKET EXECUTIVE SUMMARY
2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking
3. REGULATORY AND PATENT ANALYSIS
3.1 The United States
3.2 Europe
3.2.1 Germany
3.2.2 France
3.2.3 Italy
3.2.4 Spain
3.2.5 The U.K.
3.3 Japan
4. INTERVENTIONAL CARDIOLOGY DEVICES MARKET KEY FACTORS ANALYSIS
4.1 Interventional Cardiology Devices Market Drivers
4.1.1 Growing prevalence of cardiovascular diseases (CVDs) in the rising geriatric population
4.1.2 Technological advancements in product development
4.1.3 Increasing adoption rates of minimally invasive surgeries
4.1.4 Increasing awareness programs regarding cardiovascular diseases
4.2 Interventional Cardiology Devices Market Restraints and Challenges
4.2.1 Availability of alternative treatments
4.2.2 Product recalls
4.3 Interventional Cardiology Devices Market Opportunities
4.3.1 Increasing health awareness in emerging countries
4.3.2 Use and availability of stents – which is bio-adaptive, smart, and anti-bacterial
5. INTERVENTIONAL CARDIOLOGY DEVICES PORTER’S FIVE FORCES ANALYSIS
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry
6. COVID-19 IMPACT ANALYSIS ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET
7. INTERVENTIONAL CARDIOLOGY DEVICES MARKET LAYOUT
7.1 By Product
7.1.1 Angioplasty Balloons
7.1.1.1 Drug-Eluting Balloons
7.1.1.2 Others
7.1.2 Angioplasty Stents
7.1.2.1 Drug-Eluting Stents
7.1.2.2 Bare-Metal Stents
7.1.2.3 Bioabsorbable Stents
7.1.3 Structural Heart Devices
7.1.3.1 Aortic Valve Therapy Devices
7.1.3.2 Others
7.1.4 Catheters
7.1.4.1 Angiography Catheters
7.1.4.2 Guiding Catheters
7.1.4.3 IVUS/OCT Catheters
7.1.5 Plaque Modification Devices
7.1.5.1 Atherectomy Devices
7.1.5.2 Thrombectomy Devices
7.1.6 Hemodynamic Flow Alteration Devices
7.1.6.1 Embolic Protection Devices
7.1.6.2 Chronic Total Occlusion Devices
7.1.7 Other Devices
7.2 By Geography
7.2.1 North America
7.2.1.1 North America Interventional Cardiology Devices Market, by Product
7.2.1.2 North America Interventional Cardiology Devices Market, by Country
7.2.1.2.1 United States
7.2.1.2.2 Canada
7.2.1.2.3 Mexico
7.2.2 Europe
7.2.2.1 Europe Interventional Cardiology Devices Market, by Product
7.2.2.2 Europe Interventional Cardiology Devices Market, by Country
7.2.2.2.1 France
7.2.2.2.2 Germany
7.2.2.2.3 United Kingdom
7.2.2.2.4 Italy
7.2.2.2.5 Spain
7.2.2.2.6 Russia
7.2.2.2.7 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 Asia-Pacific Interventional Cardiology Devices Market, by Product
7.2.3.2 Asia-Pacific Interventional Cardiology Devices Market, by Country
7.2.3.2.1 China
7.2.3.2.2 Japan
7.2.3.2.3 India
7.2.3.2.4 Australia
7.2.3.2.5 South Korea
7.2.3.2.6 Rest of Asia Pacific
7.2.4 Rest of the World (RoW)
7.2.4.1 RoW Interventional Cardiology Devices Market, by Product
7.2.4.2 RoW Interventional Cardiology Devices Market, by Region
7.2.4.2.1 Middle East
7.2.4.2.2 Africa
7.2.4.2.3 South America
8. INTERVENTIONAL CARDIOLOGY DEVICES GLOBAL COMPANY SHARE ANALYSIS – KEY 3-5 COMPANIES
9. INTERVENTIONAL CARDIOLOGY DEVICES COMPANY AND PRODUCT PROFILES
9.1 Edwards Lifesciences Corporation
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4 Product Listing
9.1.5. Entropy
9.2 Abbott Laboratories
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4 Product Listing
9.2.5. Entropy
9.3 Boston Scientific Corporation
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4 Product Listing
9.3.5. Entropy
9.4 ACIST Medical Systems
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4 Product Listing
9.4.5. Entropy
9.5 F. Hoffmann-La Roche Ltd
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4 Product Listing
9.5.5. Entropy
9.6 Siemens Healthcare GmbH
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4 Product Listing
9.6.5. Entropy
9.7 Medtronic PLC.
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4 Product Listing
9.7.5. Entropy
9.8 Teleflex Incorporated
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4 Product Listing
9.8.5. Entropy
9.9 B Braun Melsungen AG
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4 Product Listing
9.9.5. Entropy
9.10 MicroPort Scientific Corporation
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4 Product Listing
9.10.5. Entropy
9.11 SIS MEDICAL AG
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4 Product Listing
9.11.5. Entropy
9.12 Lepu Medical Technology Co. Ltd.
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4 Product Listing
9.12.5. Entropy
9.13 Terumo Corporation
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4 Product Listing
9.13.5. Entropy
9.14 Sahajanand Laser Technology Limited
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4 Product Listing
9.14.5. Entropy
9.15 Biotronik SE & Co. KG
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4 Product Listing
9.15.5. Entropy
10. PROJECT APPROACH
10.1 Secondary Sources
10.2 Primary Sources
10.3 Data Triangulation
10.4 Key Expert Opinions
11. KOL VIEWS
12. DELVEINSIGHT CAPABILITIES
13. DISCLAIMER
14. ABOUT DELVEINSIGHT
